Abiopharma

KalVista Pharmaceuticals Receives Positive CHMP Opinion for Sebetralstat for the Treatment of Hereditary Angioedema Attacks

New Form 8-K - Dare Bioscience, Inc. Filed: 2025-07-25 AccNo: 0001493152-25-011402 Size: 200 KB Item 8.01: Other Events

Beyond Air Schedules First Fiscal Quarter 2026 Financial Results Conference Call and Webcast

Omeros Corporation Announces Pricing of $22 Million Registered Direct Offering

New Form 6-K - Apollomics Inc. Filed: 2025-07-25 AccNo: 0001193125-25-164849 Size: 12 KB

CareCloud Announces Preferred Stock Dividend Payments

New Form 8-K - HCA Healthcare, Inc. Filed: 2025-07-25 AccNo: 0000950170-25-098578 Size: 1 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

Phio Pharmaceuticals Announces Agreement with U.S. Manufacturing Source for Drug Substance

Canopy Growth Press Release - Canopy Growth to Report First Quarter Fiscal 2026 Financial Results on August 8, 2025

New Form 8-K - Incannex Healthcare Inc. Filed: 2025-07-25 AccNo: 0001213900-25-067474 Size: 223 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

HCA Healthcare - HCA Healthcare Reports Second Quarter 2025 Results

BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025

Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Charlene E. Gamaldo

ZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression

New Form 8-K - SENSIENT TECHNOLOGIES CORP Filed: 2025-07-25 AccNo: 0001140361-25-027250 Size: 4 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits